Semaglutide vs Retatrutide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Ozempic, Wegovy
Semaglutide is a GLP-1 receptor agonist, a peptide engineered to mimic the natural gut hormone GLP-1 but with a roughly week-long half-life so it can be dosed once weekly. It is FDA-approved and sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management, with cardiovascular benefit also on the label. This is one of the most rigorously tested peptides in existence, backed by large randomized trials, so the evidence here is in a completely different league from research-only peptides.
Also: LY3437943, Triple G
Retatrutide is the heavy hitter of the new weight-loss drugs: a once-weekly injectable peptide that hits three receptors at once - GIP, GLP-1, and glucagon - earning it the nickname triple-G agonist. In a phase 2 trial it produced some of the largest weight loss ever recorded for a drug, up to roughly 24 percent of body weight at the top dose. It is investigational, made by Eli Lilly, and not yet FDA approved as of 2026.
Key Comparison Insights
- Semaglutide is FDA approved, while Retatrutide remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Semaglutide has stronger research evidence (FDA Approved) compared to Retatrutide (Human Trials).
- Both are GLP-1 class medications compared in weight management studies.
Detailed Comparison
| Attribute | Semaglutide | Retatrutide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Semaglutide latches onto the GLP-1 receptor, the same receptor your own GLP-1 hormone uses after a meal. Activating it tells the pancreas to release more insulin when blood sugar is high, dials down glucagon (the hormone that raises blood sugar), and slows how fast the stomach empties, so you feel full longer. It also acts on appetite centers in the hypothalamus, which is the main reason it reduces hunger and drives weight loss. The molecule was modified with a fatty-acid chain that binds to albumin in the blood, which is the trick that stretches its half-life to about 160 hours and allows once-weekly injection. | Retatrutide combines three hormone signals into one molecule. The GLP-1 component curbs appetite and slows stomach emptying, the GIP component supports insulin response and may improve how fat tissue handles nutrients, and the added glucagon receptor activity is the novel piece: glucagon can increase energy expenditure and fat burning in the liver. The idea is that two arms cut how much you eat while the third raises how much you burn, which is why retatrutide is thought to push weight loss further than GLP-1-only drugs like semaglutide or even the dual GIP/GLP-1 agonist tirzepatide. The exact contribution of each receptor in humans is still being worked out, so consider the glucagon-driven energy-expenditure story a strong hypothesis rather than fully nailed down. |
| Common Dosing | 1-2.4 mg weekly (after titration) Once weekly | 4-12 mg weekly Once weekly, same day each week |
| Administration | Subcutaneous injection weekly, or oral (Rybelsus) | Subcutaneous injection weekly |
| Typical Duration | Long-term / chronic use | Long-term use expected |
| Best Time to Take | Morning, same day each week | Morning, same day each week |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The clinical evidence is extensive and high quality. The SUSTAIN program established blood-sugar control in type 2 diabetes, and SUSTAIN 6 showed a reduction in cardiovascular events. For obesity, the landmark STEP 1 trial (published in the New England Journal of Medicine in 2021) randomized nearly 2,000 adults without diabetes and found mean weight loss of 14.9% at 68 weeks on semaglutide 2.4 mg versus 2.4% on placebo, with most patients losing at least 5% of body weight. These are large, randomized, placebo-controlled trials, not pilot data. Common side effects are gastrointestinal (nausea, vomiting, constipation), usually worst during dose escalation. An oral version has also now been approved for weight loss. Unlike most peptides discussed in research circles, semaglutide is a fully approved medicine with a deep, published evidence base. | The key human evidence is the phase 2 trial by Jastreboff and colleagues, published in the New England Journal of Medicine in 2023, which randomized 338 adults with obesity (without type 2 diabetes) over 48 weeks. Mean weight reduction reached about 24 percent at the 12 mg dose, and weight loss had not clearly plateaued by week 48, hinting the ceiling could be even higher. Among participants with prediabetes at baseline, a large majority returned to normal blood sugar. Side effects were dominated by gastrointestinal issues like nausea, vomiting, and diarrhea, the familiar pattern for this drug class, and were mostly dose-dependent. These are genuinely strong phase 2 results, but they are phase 2: larger and longer phase 3 trials are underway to confirm safety and durability, and retatrutide sold outside of trials is not an approved, quality-controlled medicine. |
Frequently Asked Questions: Semaglutide vs Retatrutide
What is the difference between Semaglutide and Retatrutide?
Semaglutide is a weight loss peptide that semaglutide is a glp-1 receptor agonist, a peptide engineered to mimic the natural gut hormone glp-1 but with a roughly week-long half-life so it can be dosed once weekly. it is fda-approved and sold as ozempic and rybelsus for type 2 diabetes and as wegovy for chronic weight management, with cardiovascular benefit also on the label. this is one of the most rigorously tested peptides in existence, backed by large randomized trials, so the evidence here is in a completely different league from research-only peptides. Retatrutide is a weight loss peptide that retatrutide is the heavy hitter of the new weight-loss drugs: a once-weekly injectable peptide that hits three receptors at once - gip, glp-1, and glucagon - earning it the nickname triple-g agonist. in a phase 2 trial it produced some of the largest weight loss ever recorded for a drug, up to roughly 24 percent of body weight at the top dose. it is investigational, made by eli lilly, and not yet fda approved as of 2026. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Semaglutide or Retatrutide?
Neither is universally "better" - the choice depends on your specific goals. Semaglutide is typically used for weight loss purposes, while Retatrutide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Semaglutide and Retatrutide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Semaglutide and Retatrutide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.